Home ›
Leukemia Trials ›
NCT06580301
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YK012 administered as monotherapy in participants with B-cell acute lymphoblastic leukemia (B-ALL).
Trial Details
NCT ID NCT06580301
Phase PHASE1 / PHASE2
Sponsor Excyte Biopharma Ltd
Status RECRUITING
Cancer Type Leukemia
Interventions
Locations (sample) Guangzhou, Guangdong, China|23.11667,113.25 Guangzhou, Guangdong, China|23.11667,113.25 Guangzhou, Guangdong, China|23.11667,113.25 Guiyang, Guizhou, China|26.58333,106.71667 Zhengzhou, Henan, China|34.75778,113.64861
Key Eligibility Criteria
Participants or their legally acceptable representative must sign an ICF indicating that the participants understand the purpose of, and procedures… Eastern Cooperative Oncology Group Performance Status (ECOG) of 0-2. An estimated survival time of more than 12 weeks. A definitive diagnosis of CD19-positive B-cell acute lymphoblastic leukemia with any of the following conditions:
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →